<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837576</url>
  </required_header>
  <id_info>
    <org_study_id>LP0076-1016</org_study_id>
    <nct_id>NCT01837576</nct_id>
  </id_info>
  <brief_title>An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antipsoriatic effect of 5 different combinations&#xD;
      of calcipotriol plus betamethasone dipropionate in Daivobet® gel vehicle in compared to&#xD;
      Daivobet® gel in order to explore/find other safe and effective combination of the two&#xD;
      components.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The absolute change in Total Clinical Score (TCS) of clinical symptoms (sum of erythema, scaling and infiltration)</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in single clinical symptom score: erythema, scaling, infiltration at end of treatment and individual visits compared to baseline.</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Total Clinical Score (TCS) at individual visits compared to baseline</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute change in total skin thickness and echopoor band thickness at end of treatment compared to baseline.</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Calcipotriol plus BDP gel in different doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-E: calcipotriol, BDP gel in different concentrations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol plus BDP gel in different doses</intervention_name>
    <description>Topical , Once daily, 3 weeks</description>
    <arm_group_label>Calcipotriol plus BDP gel in different doses</arm_group_label>
    <other_name>Daivobet gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must provide written information.&#xD;
&#xD;
          -  Age 18 years or above.&#xD;
&#xD;
          -  Males, or females subjects.&#xD;
&#xD;
          -  Subjects with lesions of psoriasis vulgaris located on arms and/or legs and/or trunk.&#xD;
&#xD;
          -  Subjects with, in the opinion of the investigator, stable psoriasis&#xD;
&#xD;
          -  Subjects with psoriasis lesions(plaques)assessed by a Total Clinical Score 4 to 9&#xD;
             inclusive but each individual item ≥ 1.&#xD;
&#xD;
          -  Subjects willing and able to follow all the study procedures and complete the whole&#xD;
             study.&#xD;
&#xD;
          -  Subjects affiliated to a social security system.&#xD;
&#xD;
          -  Female of childbearing potential with a negative urine pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female subjects who are pregnant, of childbearing potential and who wish to become&#xD;
             pregnant during the study, or who are breast feeding.&#xD;
&#xD;
          -  Systemic treatment with biological therapies within 4 weeks (etanercept), 2 months&#xD;
             (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks/5 halflives&#xD;
             (whichever is longer) for experimental biological products prior to randomisation and&#xD;
             during the study.&#xD;
&#xD;
          -  Systemic treatments with all other therapies than biologicals, (e.g., corticosteroids,&#xD;
             retinoids, immunosuppressants) within the 4 week period prior to randomisation and&#xD;
             during the study.&#xD;
&#xD;
          -  Subjects using one of the following topical drugs for the treatment of psoriasis prior&#xD;
             to randomisation and during the study: Potent or very potent (WHO group III-IV)&#xD;
             corticosteroids (4 weeks).&#xD;
&#xD;
          -  Subjects using of phototherapy prior to randomisation and during the study:&#xD;
&#xD;
          -  PUVA (4 weeks)&#xD;
&#xD;
          -  UVB (2 weeks).&#xD;
&#xD;
          -  Subjects using one of the following topical drugs for the treatment of psoriasis&#xD;
             within two weeks prior to randomisation and during the study:&#xD;
&#xD;
          -  WHO group I-II corticosteroids (except if used fortreatment of scalp and/or facial&#xD;
             psoriasis),&#xD;
&#xD;
          -  Topical retinoids, Vitamin D analogues, Topical immunomodulators (e.g. macrolides),&#xD;
             Anthracen derivatives, Tar, Salicylic acid&#xD;
&#xD;
          -  Subjects using emollients on the selected plaques within one week before randomisation&#xD;
             and during the study.&#xD;
&#xD;
          -  Initiation of, or expected changes to concomitant medication that may affect psoriasis&#xD;
             vulgaris (e.g.,beta blockers, antimalarial drugs, lithium and ACE inhibitors) within 2&#xD;
             weeks prior to the randomization and during the study.&#xD;
&#xD;
          -  Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular&#xD;
             psoriasis.&#xD;
&#xD;
          -  Subjects with known/suspected disorders of calcium metabolism associated with&#xD;
             hypercalcemia within the last 10 years, based on medical history and/or subject&#xD;
             interview.&#xD;
&#xD;
          -  History of any severe disease or serious current condition which, in the opinion of&#xD;
             the Investigator, would put the subject at risk by participating in the study or would&#xD;
             interfere significantly with the evaluation of study results or the study course&#xD;
&#xD;
          -  Subjects who have accepted biopsies with a positive Hepatitis B, Hepatitis C or HIV&#xD;
             test&#xD;
&#xD;
          -  Subjects who have received treatment with any non marketed drug substance within the 4&#xD;
             week period prior to randomisation or longer, if the class of the substancerequires a&#xD;
             longer washout as defined above&#xD;
&#xD;
          -  Subjects with current participation in any other interventional clinical&#xD;
&#xD;
          -  Subjects with known or suspected hypersensitivity to component(s) of the&#xD;
             investigational products.&#xD;
&#xD;
          -  Subjects with any concomitant medical or dermatological disorder(s) which might&#xD;
             preclude accurate evaluation of the psoriasis on the test areas.&#xD;
&#xD;
          -  Subjects foreseeing an intensive solar exposure during the study or having been&#xD;
             exposed within two weeks preceding the screening visit.&#xD;
&#xD;
          -  Subjects who have accepted the biopsies with any contraindication to skin biopsy&#xD;
             procedures.&#xD;
&#xD;
          -  Subjects impossible to contact in case of emergency.&#xD;
&#xD;
          -  In the opinion of the investigator, subjects are unlikely to comply with the Clinical&#xD;
             Study Protocol.&#xD;
&#xD;
          -  Subjects who are in an exclusion period in the National Biomedical Research Register&#xD;
             of the French Ministry of Health at randomization.&#xD;
&#xD;
          -  Subject under guardianship, hospitalized in a public or private institution, for a&#xD;
             reason other than the research or subject deprived of freedom.&#xD;
&#xD;
          -  Subjects previously randomised in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Queille-Roussel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de harmacologie Clinique Appliquée à la Dermatologie (CPCAD), 06202 Nice Cedex 3, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de harmacologie Clinique Appliquée à la Dermatologie (CPCAD)</name>
      <address>
        <city>Nice</city>
        <state>Nice Cedex 3</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>July 22, 2013</last_update_submitted>
  <last_update_submitted_qc>July 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis Vulgaris</keyword>
  <keyword>Calcipotriol</keyword>
  <keyword>Betamethasone Dipropionate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

